IXICO PLC, a neuroscience imaging and biomarker analytics firm, confirmed its revenue guidance remains unchanged despite two clients cancelling Huntington's disease programs, reducing its order book by about £1.5 million over the next two years. The company noted this descoping is typical in clinical drug development and had been anticipated in its forecasts. IXICO's order book is still 21% higher than at the end of the 2025 financial year, supported by £8 million in new Huntington's program awards in the first half of the year. The company remains optimistic, expecting to meet or exceed market expectations for 2026 and 2027, with a broadening neurology pipeline including new TechBio opportunities.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Madonna returned to New York City to celebrate her No.1 album Confessions II with CLUB CONFESSIONS, a nightlife event co-hosted by MISTR that highlights dance music, queer culture, and HIV prevention. The event featured performances by Madonna and co...
Autonomix Medical has entered a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants, raising approximately $2.6 million. The investor will purchase 428,731 shares at a reduced price of $6.00 per share. In ...
Edelson Lechtzin LLP is investigating Richemont for allegedly raising prices on luxury goods due to tariffs imposed under the Trump administration and failing to refund customers after the U.S. Supreme Court ruled those tariffs unlawful in February 2...
The US government transferred nearly $297 million in seized Bitcoin and Ether to Coinbase Prime, including assets linked to criminal cases and defunct exchanges. This move does not confirm a sale but suggests consolidation or custody management, amid...
